Pancreatic Neuroendocrine Tumor
Associated Genetic Biomarkers
NCI Definition: A low or intermediate grade well differentiated tumor with neuroendocrine differentiation that arises from the pancreas. According to the presence or absence of clinical syndromes that result from hormone hypersecretion, pancreatic neuroendocrine tumors are classified either as functional or nonfunctional. 
Of the biomarker-directed therapies for pancreatic neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
There are 9 clinical trials for pancreatic neuroendocrine tumor, of which 9 are open and 0 are completed or closed. Of the trials that contain pancreatic neuroendocrine tumor as an inclusion criterion, 1 is phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (5 open).
Temozolomide, (177lutetium-dota(o)tyr3)octreotate, and 177lu-dota-octreotate are the most common interventions in pancreatic neuroendocrine tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.